Literature DB >> 16565432

Bacteriophage endolysins as a novel class of antibacterial agents.

Jan Borysowski1, Beata Weber-Dabrowska, Andrzej Górski.   

Abstract

Endolysins are double-stranded DNA bacteriophage-encoded peptidoglycan hydrolases produced in phage-infected bacterial cells toward the end of the lytic cycle. They reach the peptidoglycan through membrane lesions formed by holins and cleave it, thus, inducing lysis of the bacterial cell and enabling progeny virions to be released. Endolysins are also capable of degrading peptidoglycan when applied externally (as purified recombinant proteins) to the bacterial cell wall, which also results in a rapid lysis of the bacterial cell. The unique ability of endolysins to rapidly cleave peptidoglycan in a generally species-specific manner renders them promising potential antibacterial agents. Originally developed with a view to killing bacteria colonizing mucous membranes (with the first report published in 2001), endolysins also hold promise for the treatment of systemic infections. As potential antibacterials, endolysins possess several important features, for instance, a novel mode of action, a narrow antibacterial spectrum, activity against bacteria regardless of their antibiotic sensitivity, and a low probability of developing resistance. However, there is only one report directly comparing the activity of an endolysin with that of an antibiotic, and no general conclusions can be drawn regarding whether lysins are more effective than traditional antibiotics. The results of the first preclinical studies indicate that the most apparent potential problems associated with endolysin therapy (e.g., their immunogenicity, the release of proinflammatory components during bacteriolysis, or the development of resistance), in fact, may not seriously hinder their use. However, all data regarding the safety and therapeutic effectiveness of endolysins obtained from preclinical studies must be ultimately verified by clinical trials. This review discusses the prophylactic and therapeutic applications of endolysins, especially with respect to their potential use in human medicine. Additionally, we outline current knowledge regarding the structure and natural function of the enzymes in phage biology, including the most recent findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565432     DOI: 10.1177/153537020623100402

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  102 in total

1.  P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections.

Authors:  Ragini Gupta; Yogendra Prasad
Journal:  Curr Microbiol       Date:  2011-04-27       Impact factor: 2.188

2.  Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands.

Authors:  Mathias Schmelcher; Anne M Powell; Stephen C Becker; Mary J Camp; David M Donovan
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

3.  Rapid DNA library construction for functional genomic and metagenomic screening.

Authors:  Jonathan E Schmitz; Anu Daniel; Mattias Collin; Raymond Schuch; Vincent A Fischetti
Journal:  Appl Environ Microbiol       Date:  2007-12-14       Impact factor: 4.792

Review 4.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

5.  LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection.

Authors:  Jingmin Gu; Wei Xu; Liancheng Lei; Jing Huang; Xin Feng; Changjiang Sun; Chongtao Du; Jing Zuo; Yang Li; Taofeng Du; Linxi Li; Wenyu Han
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

Review 6.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors:  Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

Review 7.  Recombinant bacteriophage lysins as antibacterials.

Authors:  Mark Fenton; Paul Ross; Olivia McAuliffe; Jim O'Mahony; Aidan Coffey
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

Review 8.  Enhancing the utility of existing antibiotics by targeting bacterial behaviour?

Authors:  Geraint B Rogers; Mary P Carroll; Kenneth D Bruce
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 9.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

10.  The lysis system of the Streptomyces aureofaciens phage mu1/6.

Authors:  Jarmila Farkasovská; Andrej Godány
Journal:  Curr Microbiol       Date:  2008-09-25       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.